TRAILBLAZER-ALZ 2长期扩展研究结果显示，在大多数研究参与者完成治疗后，记能达依然可以持续发挥减缓疾病进展的作用；研究数据强调早期干预的重要价值，并证明有限疗程的用药方式能带来持续的长期获益。

A woman suffering from spontaneous intracranial hypotension (SIH) due to a rare CSF-venous fistula has fully recovered after ...

People are diverse, and the environments they live in may influence them differently. This broad diversity increases the need ...

The landscape of human health is undergoing profound transformation, shaped by demographic shifts, environmental challenges, and rapid technological ...

Donanemab, approved by the FDA in 2024 to treat Alzheimer's disease, is a monoclonal antibody directed at N-terminally ...

Novel imaging research indicates that young adults with a higher genetic risk for depression showed less brain activity in several areas when responding to rewards and punishments. The study also ...

In a retrospective chart review, researchers assessed the prevalence of normal vs abnormal brain MRI findings in pediatric ...

Patients with breast cancer who undergo chemotherapy may face an increased risk for brain atrophy and cognitive decline, new ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

There is only one way to fully understand neuroimaging techniques, such as electroencephalogram (EEG), which measures ...

“TRAILBLAZER-ALZ 2 LTE研究进一步证实，记能达不仅在三年中持续带来临床获益，同时也保持了稳定的安全性特征。”礼来集团方面表示，研究参与者持续获得有意义的治疗成果，这也再次证实了早期干预的长期价值。 据了解，TRAILBLAZER-ALZ 2 LTE研究是三期研究TRAILBLAZER-ALZ ...